跳至主要内容
临床试验/CTRI/2022/01/039736
CTRI/2022/01/039736招募中3 期

Fall in Ki67 Index after 2 Weeks or 4 Weeks of Preoperative Endocrine Therapy as a Means to Assess the Risk of Recurrence: A Randomized Trial

Amrita institute of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Female patients aged 18 years and above.
  • 2.Hormone receptor positive ( >1% estrogen receptor) invasive breast cancer
  • 3.Human epidermal growth factor receptor 2 negative (HER2-ve) breast cancers
  • 4.ECOG performance status 0-1
  • 5.Those who have not received chemotherapy or endocrine therapy for breast cancer in the last 5 years.
  • 6.Those who have paraffin fixed core needle tissue block or biopsy punch available for analysis for proliferative markers
  • 7.Signed informed consent

排除标准

  • 1.Pregnant or lactating women
  • 2.Prior malignancy
  • 3.Evidence of metastatic disease
  • 4.Locally advanced/ inoperable breast cancer
  • 5.High nodal burden
  • 6.Contraindication to endocrine therapy
  • 7.Inhibit or unwillingness to swallow tablets
  • 8.Patients who are not willing to participate in the study.

研究者

相似试验